Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00343720 | Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy | PHASE2 | COMPLETED | - | — | — | - | - | Mar 13, 2008 | 1 | Belgium |
| Name | Type | Description |
|---|---|---|
| VELCADE | DRUG | - |
| Alimta | DRUG | - |
Inclusion Criteria: * Men or women, 18 years of age or older * Non-small cell lung cancer (NSCLC) has been histologically or cytologically confirmed * Has relapsed or refractory locally advanced (Stage IIIb) or metastatic (Stage IV) NSCLC * Failed one prior line of systemic antineoplastic therapy f...